SIRIUS NEOSIGHT, a company specializing in the isolation of Circulating Tumor Cells (CTCs) and the development of functional tests for predicting therapeutic response in oncology, has completed a €4.4 million funding round. The financing round was secured from GO CAPITAL via its GOCA3 seed fund, DEMETER through the FAIM (Fonds d’Amorçage Industriel Métropolitain) Lyon/Saint-Etienne fund,
